AzTrials
AzTrials

Heart Failure (HF)HFcAFNCT07436299

Novel Technologies to Improve Echocardiographic Estimates of Left Ventricular Filling Pressure in Heart Failure Combined With Atrial Fibrillation

An observational study of Heart Failure (HF) and Atrial Fibrillation (AF), run by Oslo University Hospital at 15 sites in 10 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

Heart failure and atrial fibrillation are two of the most common heart diseases globally. Nearly half of all patients with heart failure also have atrial fibrillation. When heart failure and atrial fibrillation occur together, the risk of hospitalization and premature death increases significantly. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Heart Failure (HF), Atrial Fibrillation (AF)
How many people
400 participants
Where
15 sitesin 10 countries
Study dates
Sep 2026to Dec 2029
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients with atrial fibrillation undergoing clinically indicated right or left heart catheterization.

Who may be able to join

  • Atrial fibrillation (paroxysmal, persistent, or permanent)
  • Scheduled for RHC or LHC for clinical reasons
  • Able to undergo echocardiography and invasive pressure measurement within 8 hours
  • No cardiovascular medication changes between echo and catheterization
  • Written informed consent provided

Who cannot join

  • Mitral stenosis or mitral annular calcification causing severe functional stenosis
  • Severe mitral or severe tricuspid regurgitation
  • Prosthetic mitral valve
  • Atrial fibrillation with rapid ventricular response >120 bpm
  • Suboptimal echocardiographic imaging
  • Conditions rendering PCWP or LVEDP unreliable
Show all 11Show fewer
  • Pregnant women
  • Complex congenital heart disease
  • LV assist device and patients with severe non-cardiac disease with poor prognosis
  • Cardiac transplant patients
  • End-stage liver disease

Trial locations and contacts

15 sites in 10 countries. Contact the study team or a site near you to ask about taking part.

Lars-Egil Reine Hammersboen, Medical doctor contact

+4790116941

lerhammersboen@gmail.com

Otto Armin Smiseth, Professor, Medical Doctor contact

+4790867189

otto.smiseth@gmail.com

15 sites in 10 countries

United States2 sites, 2 recruiting
  • Cleveland Clinic

    Cleveland, Ohio, 44195

    Tom Wang, MD, PhD, +1 440-823-2688, WANGT2@ccf.org

    Joshua Latner, MD, +1 440-823-2688, latnerj@ccf.org

    Not yet recruiting
  • Methodist DeBakey Heart and Vascular Center

    Houston, Texas, 77030

    Bevon Lopez, +1 346-320-7421, balopez@houstonmethodist.org

    Sherif Nagueh, MD, PhD, +1 713.441.1100, SNnagueh@houstonmethodist.org

    Not yet recruiting

Other trials in United States

Belgium2 sites, 2 recruiting
  • Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium

    Aalst, 9300

    Martin Penicka, MD, PhD, +32 53 72 41 68, martin.penicka@azorg.be

    Hedwig Batjoens, +32 53 72 41 68, hedwig.batjoens@AZORG.be

    Not yet recruiting
  • Catholic University of Leuven

    Leuven, 3000

    Jens-Uwe Voigt, MD, PhD, +32 16 34 90 16, jens-uwe.voigt@uzleuven.be

    Jens-Uwe Voigt, MD, PhD

    Not yet recruiting

Other trials in Belgium

France2 sites, 2 recruiting
  • Laboratory Signal Processing and Image, Department of Cardiology

    Rennes, 35033

    Erwan Donal, MD, PhD, +33 (0)2 23 23 62 20, erwan.donal@gmail.com

    Erwan Donal, MD, PhD

    Not yet recruiting
  • Service de Cardiologie, Hôpitaux Universitaires de Strasbourg

    Strasbourg, 67091

    Elena Galli, MD, PhD, +33 03 88 11 67 68, gallelena@gmail.com

    Elena Galli, MD, PhD

    Not yet recruiting

Other trials in France

Japan2 sites, 2 recruiting
  • Nagoya City University Graduate School of Medical Sciences

    Nagoya, Aichi-ken, 467-8601

    Nobuyuki Ohte, MD, PhD, +81-90-4269-6549, ohte@812@gamail.com

    Nobuyuki Ohte, MD, PhD

    Not yet recruiting
  • Ehime University

    Tōon, Ehime, 791-0295

    Katsuji Inoue, MD, PhD, +81 89-964-5111, katsujiinoue2@gmail.com

    Katsuji Inoue, MD, PhD

    Not yet recruiting

Other trials in Japan

United Kingdom2 sites, 2 recruiting
  • Department of Cardiovascular Sciences, University of Birmingham

    Birmingham

    Karina Bunting, PhD, MSc, BSc, +44 (0) 7500 872257, k.v.bunting@bham.ac.uk

    Karina Bunting, PhD, MSc, BSc

    Not yet recruiting
  • King's College

    London, WC2R2LS

    Pablo Lamata, MSc, PhD, +44 (0)20 7836 5454, pablo.lamata@kcl.ac.uk

    Joao Filipe Fernandes, MDc, PhD, +44 (0)20 7836 5454, jf.fernandes@kcl.ac.uk

    Not yet recruiting

Other trials in United Kingdom

New Zealand1 site, 1 recruiting
  • University of Auckland

    Auckland, Auckland, 1010

    Debbie Zhao, MSc, PhD, +64 9 373 7999, debbie.zhao@auckland.ac.nz

    Martyn Nash, MSc, PhD, +6493737599 Ext.82550, martyn.nash@auckland.ac.nz

    Not yet recruiting

Other trials in New Zealand

Norway1 site, 1 recruiting
  • Division of Cardiovascular & Pulmonary Diseases, Oslo University Hospital

    Oslo, Oslo, 0424

    Lars Egil Reine Hammersboen, MD, 90116941, lerhammersboen@gmail.com

    Otto Armin Smiseth, MD, PhD, +4790867189, otto.smiseth@gmail.com

    Recruiting

Other trials in Norway

Romania1 site, 1 recruiting
  • Carol Davila University of Medicine and Pharmacy

    Bucharest, 020021

    Bogdan Popescu, MD, PhD, +40 21 318 0719, bogdan.a.popescu@gmail.com

    Bogdan Popescu, MD, PhD

    Not yet recruiting

Other trials in Romania

Slovenia1 site, 1 recruiting
  • The Department of Cardiology at the Ljubljana University Medical Centre

    Ljubljana, SI-1525

    Marta Cvijic, MD, PhD, +386 1 522 50 50, marta.cvijic@gmail.com

    Marta Cvijic, MD, PhD

    Not yet recruiting

Other trials in Slovenia

South Korea1 site, 1 recruiting
  • Yonsei University College of Medicine

    Seoul, Seoul, 03722

    Jong-Won Ha, MD, PhD, +82-33-741-0211, JWHA@yuhs.ac

    Jong-Won Ha, MD, PhD

    Not yet recruiting

Other trials in South Korea

About this study

Official title: Novel Technologies to Improve Echocardiographic Estimates of Left Ventricular Filling Pressure in Heart Failure Combined With Atrial Fibrillation: A Prospective Multicenter Study

Heart failure and atrial fibrillation are two of the most common heart diseases globally. Nearly half of all patients with heart failure also have atrial fibrillation. When heart failure and atrial fibrillation occur together, the risk of hospitalization and premature death increases significantly. However, there is a lack of reliable tools to assess how severely the heart is affected in these patients. This makes it difficult both to establish the correct diagnosis, tailor treatment, and predict who is at greatest risk of hospital admission or death from the disease.

One of the most important targets in heart failure is the filling pressure in the left ventricle. When this pressure is high, it means that the heart has difficulty receiving blood, leading to shortness of breath and fluid retention in the body. Today, filling pressure is usually estimated using ultrasound (echocardiography), but the available methods are primarily developed for patients without atrial fibrillation. In patients with both heart failure and atrial fibrillation, the measurements are so uncertain that they cannot be used as a reliable basis for clinical decision-making.

Read more

In this study, entitled Heart Failure combined with Atrial Fibrillation (HFcAF), the investigators will test new ultrasound methods that combine novel measures of cardiac chamber function with established techniques. Artificial intelligence will be used to identify the most useful combinations of parameters, select cardiac cycles that are best suited for analysis in atrial fibrillation, and automate and optimize the measurements. This approach may provide both more accurate and faster assessments, while also making the methods easier to implement in clinical practice. The aim is to improve the estimation of filling pressure so that it becomes more precise also in patients with atrial fibrillation. The investigators will then examine whether these improved methods can be used to predict which patients are at highest risk of hospitalization or death due to heart failure.

The study is designed as a prospective multicenter study, in which patients are recruited from several hospitals in different countries. This will make the results robust and generalizable to a wide range of patient populations. The investigators anticipate that the project will pave the way for better diagnostics and risk stratification in heart failure combined with atrial fibrillation and, in the longer term, contribute to improved guidelines and treatment for a large number of patients. If successful, the project will provide a new tool that can contribute to earlier and more targeted treatment, thereby improving quality of life and prognosis for a large group of patients.

Read the detailed description

Study Design:

This is a prospective, multicenter study of atrial fibrillation (AF) patients referred for right or left heart catheterization (RHC/LHC). The primary objective will be to develop and validate a clinically applicable algorithm combining echocardiographic and clinical parameters to differentiate normal from elevated left ventricular (LV) filling pressure (LVFP) in AF with ≥80% diagnostic accuracy. Secondary objectives will be to identify imaging predictors of abnormal pulmonary capillary wedge pressure (PCWP) elevation during exercise and to identify prognostic imaging markers associated with mortality and heart-failure outcomes over a 3-year follow-up period.

LVFP will be measured as PCWP during RHC and as LV end-diastolic pressure (LVEDP) during LHC. In cases studied during left atrial (LA) interventions, LA mean pressure will be used as a measure of LVFP. Echocardiography will be performed during, immediately before, or immediately after catheterization (≤8 hours separation, without cardiovascular medication changes). A dedicated exercise substudy will investigate imaging predictors of abnormal PCWP rise during exertion.

Recruitment of at least 400 patients is considered feasible based on experience from a previous international multicenter AF study. Patients will be recruited from 15 centers in the USA, Europe, Asia, and New Zealand over a period of 1.5 to 2 years.

Data collection:

A 12-lead electrocardiogram (ECG) and standard clinical data, including cuff blood pressure and standard blood tests with NT-proBNP, will be recorded.

Echocardiographic Imaging:

Echocardiographic measurements will be performed according to most recent American Society of Echocardiography / European Association of Cardiovascular Imaging guidelines. In addition, LA and right atrial (RA) strains will be measured. Echocardiographic recordings will be obtained by experienced investigators without knowledge of the invasive data. A core lab for echo analysis will be established. A minimum of 10 consecutive heartbeats will be recorded. Echo will be performed either simultaneously or within 8 hours of hemodynamic assessment. Equipment from different vendors will be used. Three-dimensional echocardiography will be used in selected patients.

Key Echocardiographic Views and Measurements

  • Apical 4-chamber LV-focused: mitral inflow, tissue Doppler early diastolic velocity (e') (septal, lateral, average), systolic velocity (s'), isovolumetric relaxation time, LV global longitudinal strain (GLS), LV volumes and ejection fraction, LV mass
  • Apical 4-chamber LA-focused: pulmonary vein Doppler (S and D velocities and their velocity-time integrals), LA strain, LA volumes
  • Apical 5-chamber: aortic valve continuous-wave (CW) Doppler
  • Apical 2- and 3-chamber: LV GLS, focused LV/LA imaging
  • Right ventricular / pulmonary artery evaluation: tricuspid regurgitation velocity, right ventricular outflow tract (RVOT) pulsed-wave Doppler, RVOT acceleration time
  • Subcostal inferior vena cava (IVC) view: IVC diameter and collapsibility.
  • RA-focused view: RA reservoir strain

Cardiac Catheterization:

LVFP >15 mmHg will be considered elevated. LVFP will be averaged over 10 beats during end-expiration, using an index beat approach for selection of heart cycles.

Bicycle ergometer in supine position with simultaneous RHC will be performed in patients scheduled for this procedure as part of a diagnostic work-up and will be performed according to current clinical routine. This includes pressure measurements and focused echocardiographic study at rest and at peak exercise. The rate of pedaling will be 60 rotations per minute, and the workload will increase gradually to a moderate level.

Outcome Data:

All-cause mortality and heart failure hospitalizations will be the primary clinical outcomes. Outcome analysis will be extended to 3 years of follow-up.

Data Management and Analysis:

All imaging and invasive pressure measurements will be analyzed with investigators blinded to the corresponding data. Echocardiography will be reviewed centrally at the Echo Core Laboratory. Statistical analyses will include descriptive statistics, logistic regression, receiver operating characteristic curve analysis, and supervised machine-learning methods to derive a diagnostic algorithm. A two-sided P value <0.05 will be considered statistically significant.

Study Flowchart:

  1. Screening → 2. Consent → 3. Clinical assessment \& ECG → 4. Echocardiography → 5. RHC/LHC (± exercise) → 6. Data transfer to core labs → 7. Follow-up → 8. Analysis
Keywords
Heart failure, Atrial fibrillation, Echocardiography, Filling pressure, Diastolic function
Medical subject headings
Heart Failure, Atrial Fibrillation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07436299
Study groupRoleWhat they receive
Patients with atrial fibrillation referred for right- or left-heart catheterizationWe will recruit patients >18 years with established or suspected heart failure who have atrial fibrillation and are referred to a diagnostic right- or left-sided heart catheterization or interventional procedures via the left atrium. Balanced numbers with normal and reduced left venticular ejection fraction, balanced representation of sexes, of short (<1year) and long-lasting duration of atrial fibrillation will be attempted.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Diagnostic accuracy of a non-invasive algorithm for classification of left ventricular filling pressure in atrial fibrillation

    Main aim of the study is to develop and validate a clinically applicable algorithm combining echocardiographic and clinical parameters to differentiate normal from elevated LV filling pressure in AF with ≥80% diagnostic accuracy. Left venticular filling pressures will be measured during right- or left-sided heart catehterization and left ventricular filling pressure >15 mmHg will be considered elevated.

    Measured: • Start recruitment: February 2026 • End recruitment: January 2028 • Follow-up: 3 years • Data analysis: Ferbuary 2026 - December 2028. Outcome analysis will be extended to 3 years of follow-up. • Manuscript preparation: December 2028 - December 2029

  2. Imaging markers associated with mortality and heart-failure hospitalization in atrial fibrillation

    To identify prognostic imaging markers associated with mortality and heart-failure hospitalization over a 3-year follow-up period.

    Measured: • Start recruitment: February 2026 • End recruitment: January 2028 • Follow-up: 3 years • Data analysis: Ferbuary 2026 - December 2028. Outcome analysis will be extended to 3 years of follow-up. • Manuscript preparation: December 2028 - December 2029

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Feb 2026
  2. Study startSep 2026 (estimated)
  3. Primary completionJan 2028 (estimated)
  4. Study completionDec 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
400 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07436299
Sponsor's protocol ID
964539
Other IDs
52438
Acronym
HFcAF
Status last verified
Sep 2026
First submitted
21 Feb 2026
Last updated
10 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: De-identified individual participant data (IPD) underlying the results reported in this study, including the data dictionary, will be made available to qualified researchers upon reasonable request. Supporting documents, including the study protocol, statistical analysis plan, and analytic code, will also be available.

Publications

  • Nagueh SF, Sanborn DY, Oh JK, Anderson B, Billick K, Derumeaux G, Klein A, Koulogiannis K, Mitchell C, Shah A, Sharma K, Smiseth OA, Tsang TSM. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography and for Heart Failure With Preserved Ejection Fraction Diagnosis: An Update From the American Society of Echocardiography. J Am Soc Echocardiogr. 2025 Jul;38(7):537-569. doi: 10.1016/j.echo.2025.03.011.

    PubMed 40617625
  • Khan FH, Zhao D, Ha JW, Nagueh SF, Voigt JU, Klein AL, Gude E, Broch K, Chan N, Quill GM, Doughty RN, Young A, Seo JW, Garcia-Izquierdo E, Monivas-Palomero V, Mingo-Santos S, Wang TKM, Bezy S, Ohte N, Skulstad H, Beladan CC, Popescu BA, Kikuchi S, Panis V, Donal E, Remme EW, Nash MP, Smiseth OA. Evaluation of left ventricular filling pressure by echocardiography in patients with atrial fibrillation. Echo Res Pract. 2024 Jun 3;11(1):14. doi: 10.1186/s44156-024-00048-x.

    PubMed 38825684
  • Gomez-Outes A, Lagunar-Ruiz J, Terleira-Fernandez AI, Calvo-Rojas G, Suarez-Gea ML, Vargas-Castrillon E. Causes of Death in Anticoagulated Patients With Atrial Fibrillation. J Am Coll Cardiol. 2016 Dec 13;68(23):2508-2521. doi: 10.1016/j.jacc.2016.09.944.

    PubMed 27931607
  • Zafrir B, Lund LH, Laroche C, Ruschitzka F, Crespo-Leiro MG, Coats AJS, Anker SD, Filippatos G, Seferovic PM, Maggioni AP, De Mora Martin M, Polonski L, Silva-Cardoso J, Amir O; ESC-HFA HF Long-Term Registry Investigators. Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry. Eur Heart J. 2018 Dec 21;39(48):4277-4284. doi: 10.1093/eurheartj/ehy626.

    PubMed 30325423
  • Jones NR, Smith M, Yang Y, Hobbs FDR, Taylor CJ. Trends in mortality in people with heart failure and atrial fibrillation: a population-based cohort study. Lancet Healthy Longev. 2025 Aug;6(8):100734. doi: 10.1016/j.lanhl.2025.100734. Epub 2025 Aug 13.

    PubMed 40818479

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in